Spelling suggestions: "subject:"dorsomorphin"" "subject:"casomorphin""
1 |
Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidines and (4-Hydroxy-6-trifluoromethylpyrimidin-2-yl) guanidinesSingleton, Justin Dave 02 August 2021 (has links)
A microwave reactor was used to synthesize a series of novel 3,6-disubstituted or 3-substituted pyrazolo[1,5-a]pyrimidines in a total of 1 hour reaction time over 3 steps. The products were obtained in good to excellent yields (34-92%, ave = 52%) using a straightforward synthesis starting with the reaction of dimethylformamide-dimethylacetal with commercially available aryl acetonitriles (120C, 20 min). This was followed by treatment with H2NNH2 • HBr (120C, 20 min), and then reacted with either 1,1,3,3-tetramethoxypropane or a 2-aryl-substituted malondialdehydes (120C, 20 min). The resulting product was either collected on a sintered glass funnel or purified via column chromatography. The compounds were screened for anti-cancer activity against A2780 Ovarian and/or MCF7 breast cancer cell lines in vitro. The most active compounds were the 3-(4-(trifluoromethyl)phenyl)-6-[4-(2-(piperidin-1-yl)ethoxy]phenyl analogue and the 3-(2-fluorophenyl)-6-[4-(2-(4-methylpiperzin-1-yl)ethoxy]phenyl analogue, exhibiting EC50 values of 0.84 and 0.52 M respectively, which is 2-3 times more potent than Dorsomorphin. Several of the derivatives also showed promising activities against several viruses of emerging concern, including HBV, MERS Coronavirus, Zika, and Ebola. Use of a microwave reactor to synthesize N’-aryl/(alkyl) substituted N-[(4-hydroxy-6-phenyl)pyrimidin-2-yl]guanidines or N-[(4-hydroxy-6-trifluoromethyl)pyrimidin-2-yl]guanidines from the corresponding cyanamides with alkyl/aryl amines was achieved in good to excellent yields (39-96%, ave = 62%) in 10 minutes at 120C using only 1 equivalent of amine. Work-up was exceptionally simple, and involved collecting precipitated solids on a sintered glass funnel and washing with cold 2-propanol. Products were obtained in analytically pure form and required approximately 1 hour to prepare, start to finish. Compounds in this series showed early promise as potential inhibitors of A2780 Ovarian cancer, in vitro.
|
2 |
Synthesis and Anticancer Evaluation of Novel Pyrazolo[1,5-a]pyrimidines: Discovery of a Novel Lead Compound with Selective Activities Against VPS34 and JAK1-JH2 PseudokinaseDass, Reuben 10 August 2022 (has links) (PDF)
A library of 25 novel 3,6-disubstituted and 3-substituted pyrazolo[1,5-a]pyrimidines were synthesized using a microwave chemical reactor in 3 steps with a total reaction time of 1 hour. The products were obtained in good to excellent yields (20-93%, ave. = 62%). The synthesis began with the reaction of aryl acetonitriles with dimethylformamide-dimethylacetal (120C, 20 min), followed by treatment of the resulting 2-arylacrylonitrile with H2NNH2 • HBr (120C, 20 min). The intermediate 4-arylpyrazol-5-amine obtained was finally reacted with either 2-aryl-substituted malondialdehydes or 1,1,3,3-tetramethoxypropane (120C, 20 min) to give the final products. The products were either collected directly on a Buchner funnel or purified via flash chromatography. The compounds were screened for anti-cancer activity against the A2780 Ovarian cancer cell line in vitro at 10 µM. The most active compound was the 2-(pyrazolo[1,5-a]pyrimidin-3-yl)benzothiazole, herein referred to as RD-I-53, which had an EC50 value of 0.9 µM nearly mirroring the experimental control, Dorsomorphin, which had an EC50 of 1.1 µM. RD-I-53 was screened against a panel of 453 kinases by DiscoverX in a KinomeScan™, a competitive binding inhibition assay wherein RD-I-53 selectively inhibited VPS34 kinase and JAK1-JH2 pseudokinase (Kd VPS34 = 0.4µM, Kd JAK-1 JH2 = 0.5µM). NCI-60 data revealed selective anticancer activity of RD-I-53 against the MCF-7 and MDA-MB-468 breast cancer cell lines. Virtual docking studies of RD-I-53 against the VPS34 active site and its derivatives resulted in the creation of a virtual library of new compounds with potentially improved anticancer activity. A highly convergent route was developed to facilitate the ease of access to derivatives of RD-I-53. In the process, new methodologies for the synthesis of 2-aminobenzothiazoles and the thiocyanation of non-C4-substituted anilines and heterocycles were investigated and reported. A library of derivatives of RD-I-53 has been synthesized to be screened for potentially improved kinase inhibitory and anti-cancer activity.
|
Page generated in 0.3654 seconds